Key Takeaways
- Base business navigates a demand trough: Organic chemicals revenue fell 5% YoY and inorganic fell 30% YoY as agrochemical and pharma destocking, falling raw material prices, and geopolitical disruption all hit simultaneously.
- One-time inventory losses scar the quarter: Liquidation of high-cost lithium inventory at BuLi Chem and Neogen together created a ₹7-7.5 crore hit, with the majority now absorbed and normalization expected from Q1 FY25.
- Battery pivot is now in commissioning, not planning: Trial production has begun on the 400 MT lithium salt facility, the Dahej electrolyte plant targets commissioning by Q4 FY24, and land is secured for the 30 KTA Pakhajan plant.
- CSM progress is real but demand visibility is poor: CSM now contributes 14-15% of revenue and 9-10 molecules are approved, yet management has no good clarity on demand at least through H1 FY25.
- What to watch next quarter: Whether any battery revenue materializes before March 2024, the pace of pharma demand recovery, and the finalization of project finance terms for the Pakhajan electrolyte plant.
Base Business: Demand & Recovery
- Agro is the deeper wound: Agro contributed 20-25% of the base business and was mostly international or India-linked-to-international, so the export decline has been significant. Supply chain partners guiding that agro demand visibility will only emerge in H2 of the calendar year when customers begin planning for 2025.
- Pharma is patchy but mending: Some pharma customers have already recovered, some are still recovering. Antiretrovirals and specific large molecules for heart-related ailments still face inventory corrections, while more niche pharma segments have already bounced back.
- Revenue gap filled by low-preference work: The company manufactured more pharma generic India molecules this quarter, molecules it normally does not do, to make up for the demand shortfall.
- BuLi Chem customers returning: After six months of low demand, existing BuLi Chem customers are now starting to consume N-Butyl lithium on a regular basis, and new customers have been onboarded in India and international markets.
- Lithium prices near a floor: Lithium carbonate is at a 30-year historical low average of $10-$12, below the $20-$25 most predicted as a long-term stable price. Management does not see further decreases because newer Australian mining companies would become unviable.
Dr. Harin Kanani: "We had an option either to wait longer for prices to recover. But since we didn't see serious price recovery happening immediately, we decided to go ahead and sell at what is today's market price."
Battery Chemicals: Build-out & Timelines
- Salt capacity being pulled forward: The original 4,000 MT salt capacity plan has been raised to 5,500 MT because customers cannot wait for the greenfield facility. The Dahej component alone has been increased from 1,000 MT to 2,500 MT.
- Phased commissioning underway: Trial production on the first 400 MT has commenced. The plan targets 1,000 MT and then 1,500 MT online in Q2 or Q3 FY25, with 2,500 MT by end of Q4 FY25. A further 3,000 MT gets added in FY26.
- Electrolyte plant ready for customer trials: The 2,000 MT Dahej electrolyte facility is scheduled for commissioning by end of Q4 FY24 so that initial samples can be provided to customers.
- 30 KTA Pakhajan plant on track: Land acquisition complete, Mitsubishi plant design finalized, permissions expected by March, construction to start by March or April, with operations targeted for H2 FY26, around December 2025 plus or minus one quarter.
- Customer approvals expected soon: Electrolyte salt customer approvals expected to start coming through by end of Q4 FY24, with revenue starting by end of Q4 FY24 or early Q1 FY25.
- International salt demand is structural: Strong interest exists for non-Chinese electrolyte salt and additive supply, driven by the IRA and heavy dependence on China. Salts are easier to export internationally than electrolytes because customers already import salt from China, so switching to India is not a big change.
- Full utilization expectations: The 2,000 MT electrolyte facility is expected to run at full capacity within 18-21 months from a March 2024 start. The 30 KTA plant, starting end of FY26, may reach full utilization only in FY28 or FY29.
Dr. Harin Kanani: "Therefore, when we offer a salt, the question that remains is that instead of importing from China, I have to import from India. That is why we are not making a very big change from what is already being done. That is the reason why salts are easier to export to the international market whereas electrolytes are usually made locally."
Margins & Profitability
- EBITDA under pressure from expansion costs: Higher employee costs and other expenses tied to the Neogen Ionics build-out, plus the one-time inventory liquidation losses, compressed EBITDA. Gross margins were largely maintained.
- PAT hit by multiple one-offs: Higher finance costs, higher depreciation, and a one-time tax charge from the transition to the new tax regime all weighed on PAT. The effective tax rate will be lower from next year.
- Inventory losses now largely behind: The ₹4.5-5 crore BuLi Chem loss and ₹2.5 crore Neogen loss have been absorbed. Some impact will carry into Q4, but Q1 FY25 onwards should be back to normal.
- Base business margin ambition: Management targets better product selection in the base business and improved EBITDA margins as full utilization levels are reached in FY26.
- Battery margin assumption is a floor, not a forecast: The 18% EBITDA margin assumption for the battery chemicals business is derived from a 20%+ ROCE target. Management views this as the bare minimum needed to justify the first-mover risk and investment.
Dr. Harin Kanani: "The basis for our assumption is that we are looking at, if we are doing an investment, we are taking the risk, if we are the first mover and to be able to justify the risk and the investment, this is the bare minimum that we need."
CSM & the Pipeline
- CSM has hit its revenue band: CSM now contributes 14-15% of revenue, within the stated 10-20% goal. Advanced intermediates and CSM together are at ~30%, moving toward the 40% target.
- Relationships are broadening but demand is not: Nine to ten different molecules have been done for different agro companies, and more agrochemical companies have approved Neogen. However, most customers do not have large demand in the next year, and management has no good clarity at least through H1 FY25.
- Flavour and fragrance is the bridge: Flavour and fragrance and other non-pharma, non-agro industries have supported CSM while agro demand remains absent.
- Dahej site unlocks large-agro conversations: Once the Dahej site is commissioned, the company will start talking to the large five agrochemical companies in Europe and the US. Discussions have been initiated and evaluation work has started.
- R&D lab expansion is a pipeline play: The expanded R&D lab in Karakhadi, coming online sometime in the next financial year, is intended to start relationships early in pharma, not for immediate revenue but to build the pipeline.
Dr. Harin Kanani: "While the number of relationships have increased, the number of molecules have increased, but still we don't have a very good clarity at least in the first half of the next financial year."
India Battery Ecosystem & Competitive Position
- India cell manufacturing is starting now: Battery capacities should come online in calendar year 2024, with 1-2 GWh level projects starting, ramping up in early 2025, more in H2 2025, and significant capacity expected by 2026. These initial plants will not be fully optimized or running at full capacity but will start manufacturing cells.
- Management confident on India vs China competitiveness: Management believes Indian companies, with initial plans of 10, 20, and some considering ultimate 50 or 100 GWh volumes, have captured the majority of scale benefits needed and will be competitive against China in fair competition.
- Cathode entry gated by binding commitment: Neogen will move ahead into cathode only with a very firm, binding contract or a joint development or joint plan. It will not venture without strong business clarity and committed customer clarity.
- Electrolyte localization is a moat: Electrolyte requires very low moisture, very low acidity, very low impurities, and some additives need sub-10°C temperatures. Transporting requires specialized high-cost tanks, and with multiple customers and multiple chemistries, local manufacturing is always preferred.
Dr. Harin Kanani: "For cathode we will move ahead only when we have a very firm, binding contract or a kind of joint development or a joint plan. Some such situation is only when we will basically venture into a cathode area."
Balance Sheet & Funding
- Project finance in advanced talks: The company is in very advanced stages of discussions with lenders who want to provide very long-term project finance on preferential terms to manage debt service coverage ratios.
- Equity raise sufficient for now: The recently raised equity is sufficient, and banks and financial institutions are satisfied. Whether further equity is desirable will depend on how fast the base business recovers, how BuLi contributes, and how electrolyte salt and capacity are phased. A view will be taken as the year progresses.
- Debt comfort zone defined: Management ideally wants debt to EBITDA below 3x, acknowledges it will be high for a certain period, and says that call will be taken at that time.
- Gross debt snapshot: Gross long-term debt is approximately ₹150 crore, with working capital debt of approximately ₹200-250 crore, per management's rough estimates on the call.
- CAPEX funded through a mix: Investments are being done in a phased manner, funded through a mix of debt, internal accruals, and the recently raised equity.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Battery sales start | Internal target to begin some battery sales | Before March 2024 |
| Dahej electrolyte facility commissioned | 2,000 MT facility ready for customer trials | End of Q4 FY24 |
| Electrolyte salt customer approvals | Approvals start coming through; revenue begins | End of Q4 FY24 to early Q1 FY25 |
| Pakhajan 30 KTA plant construction start | Permissions expected, construction begins | March-April 2024 |
| Pakhajan 30 KTA plant operational | Plant commissioned | H2 FY26, around December 2025 (±1 quarter) |
| Salt capacity phased commissioning | 1,000 MT, then 1,500 MT, then 2,500 MT online | Q2/Q3 FY25 through end of Q4 FY25 |
| Additional salt capacity | 3,000 MT added | FY26 |
| Inventory impact normalized | High-cost inventory impact fully behind | Q1 FY25 onwards |
| Base business EBITDA improvement | Better product selection, full utilization | FY26 |
| Brownfield SOC expansion | Remaining 29 m³ commissioned depending on business needs | During FY25 |
| Cathode entry | Only with firm binding contract or joint development plan | Condition-based, no timeline |
Key Metrics
| Metric | Q3 FY24 |
|---|---|
| Consolidated revenue | ₹164.4 cr, down 12% YoY |
| Standalone revenue | ₹167.4 cr, vs ₹186.3 cr YoY |
| Consolidated EBITDA | ₹20.4 cr, impacted by higher employee costs, Neogen Ionics expenses, and BuLi Chem inventory liquidation |
| Standalone EBITDA | ₹25.8 cr, vs ₹30.1 cr YoY |
| Consolidated PAT | ₹1.1 cr, includes higher finance costs, depreciation, and one-time tax charge on transition to new tax regime |
| Standalone PAT | ₹5.8 cr, vs ₹14.7 cr YoY |
| Organic Chemicals revenue | ₹129 cr, down 5% YoY; would have been higher by ₹12 cr adjusting for bromine and RM price drop |
| Inorganic Chemicals revenue | ₹35 cr, down 30% YoY; would have been higher by ₹23 cr adjusting for lithium raw material price fall |
| Domestic to export mix | 78% to 22% |
| CSM business contribution | 14% to 15% of revenue |
| Advanced intermediate and CSM combined contribution | ~30% of revenue, vs target of 40% |
| Inventory loss from lithium price fluctuation | ₹4.5 cr to ₹5 cr on BuLi Chem, ₹2.5 cr on Neogen |
| Gross long-term debt | ~₹150 cr; working capital ₹200-250 cr |
| Aggregate CAPEX for FY24 and beyond capacities | close to ₹1,500 cr, with peak revenue potential of ₹2,500 cr to ₹2,950 cr depending on lithium prices |
| Electrolyte salt capacity expansion target at Dahej SEZ | 2,500 metric tons in phases during FY25, up from earlier 1,000 metric tons plan |